medigraphic.com

2005, Número 4

<< Anterior Siguiente >>

Rev Mex Anest 2005; 28 (4)


Actualidades en inotrópicos

Carrillo-Esper R, Sánchez-Zúñiga MJ

Idioma: Español
Referencias bibliográficas: 41
Paginas: 208-216
Archivo PDF: 112.60 Kb.


RESUMEN

La falla cardíaca es un síndrome complejo secundario a activación inflamatoria y neurohumoral, inbalance autonómico y disfunción endotelial. Para manejar la disfunción cardíaca se han utilizado diversos fármacos con diferentes mecanismos de acción dirigidos a regularizar y potenciar la función contráctil, pero que no modifican la progresión de la enfermedad. El abordaje terapéutico actual además de optimizar el inotropismo por la activación de procesos moleculares de movimiento de calcio, se enfoca en la modulación de las señales que activan los procesos que controlan la remodelación cardíaca, como la fibrosis y la hipertrofia.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Karman B. The pathophysiology of advances heart failure. Am Heart J 1998;135:S216-230.

  2. Gary SF. Pathophysiology of chronic heart failure. Am J Med 2001;110:S7A.

  3. Pedemonte SF. Nuevos inotrópicos. Rev Col Anest 1996;24:29-32.

  4. Endoh M. Mechanism of action of novel cardiotonic agents. J Cardiovas Pharmacol 2002;40:323-338.

  5. Mercadier JJ. Altered Sarcoplasmic reticulum Ca++- ATPase gene expression in the human ventricule during and-stage heart failure. J Clin Invest 1990;85:305.

  6. Brittsma AG. Phospholamban and cardiac contractile function. J Moll Cell Cardiol 2000;32:2131-9.

  7. Figgitt DP. Levosimendan. Drugs 2001;61:613-627.

  8. Lehtonen LA. Levosimendan: A promising agent for the treatment of hospitalized patients with decompensated heart failure. Curr Cardiol Res 2002;2:233-243.

  9. Lehtonen LA. Levosimendan: Un calcio sensibilizante parenteral con efectos vasodilatadores adicionales. Expert Opin Investing Drugs 2001;10:955-971.

  10. Haikala H. Cardiac Troponin C as a target protein a for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol 1995;27:1859-66.

  11. Levijoki J. Futher evidence for the cardiac troponin C mediated calcium sensitization by levosimendan structure-respons and binding analysis with analog of levosimendan. J Mol Cell Cardiol 2002;32:479-91.

  12. Anders O. Effect of levosimendan a novel inotropics calcium sensitizing drugs in experimental septic shock. Crit Care Med 2001;29:2185-2193.

  13. Parissis JT. Effects of levosimendan on circulating proinflammatory mediators in patients with decompensated advances heart failure. Am J Cardiol 2002;93:124-139.

  14. Ronco JJ. Anti-Inflammatory Effects of inotropics drugs in the treatment of septic Shock: Another Piece to de Puzzle. Crit Care Med 2001;29:1837-1838.

  15. Frishman HW. Advances in positive Inotropic Therapy: Levosimendan. Crit care Med 2003;31:167-75.

  16. Follath F. Efficacy and safety of intravenous levosimendan compared with dobutamina in severe low-output heart failure. (The LIDO Study). Lancet 2002;360:1996-202.

  17. Moiseyev VS. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. Eur Heart J 2002;23:1422-1432.

  18. Nieminen MS; et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll cardiol 2002;36:1903-12.

  19. Lilleberg J. Dose-range study of a new calcium sensitizer, levosimendan in patients with left ventricular dysfunction. J Cardiovasc Pharmacol 1995;26:S1 63-9.

  20. Hosenpud JD, et al. For the oral Levosimendan Study Group: Levosimendan a novel myofilament calcium sensitizer allows weaning of parental inotropics therapy in patients with severe congestive heart failure. Am J Cardiol 1999;11:78-85.

  21. Lawrence B, et al. Pharmacodynamics effects of milrinone with are without a bolus loading infusion. Am Heart J 2000;141:e6.

  22. Colucci WS. Myocardial and vascular actions of milrinone. Eur Heart J. 1989;10:SC32-8.

  23. Givertz MM, et al. Effects of bolus milrinone on hemodynamic variable and pulmonary vascular resistance in patients with severe left ventricular dysfunction. A rapid tests for reversibility of pulmonary hypertension. J Am Coll Cardiol 1996;28:1775-80.

  24. Parker M, et al. Effects of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study. N Engl J Med 1991;325:1468-75.

  25. Feneck RO. Effects of variable dose milrinone in patients with low cardiac output after cardiac surgery. Am Heart J 1991;121:1995-99.

  26. Karlsberg RP, et al. Comparative efficacy of short-term intravenous infusions of milrinone and dobutamine in acute congestive heart failure following acute myocardial infarction. Milrinone-Dobutamine Study Group. Clin Cardiol 1996;19:21-30.

  27. Lobato EB. Effects of milrinone versus epinephrine on grafted mammary artery flow after cardiopulmonary bypass. J Cardiothoracic Vasc Anesth 2000;14:9-11.

  28. Loh E, et al. A randomized multicenter study comparing the efficacy and safety of intravenous milrinone and intravenous nitroglycerin in patients with advances heart failure. J Cardiac Fail 2001;7:114-21.

  29. Silver MA. Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbation of Chronic Heart Failure (OPTIME_CHF) Investigators. JAMA 2002;87:1541-7.

  30. Levin EL. Natriuretic peptides. N Engl J Med. 1998;339:321-8.

  31. Rubattu S, et al. The atrial natriuretic peptide: a changing view. J Hyper 2001;19:1923-31.

  32. Sagnella GA. Atrial natriuretic peptide mimetic and vasopeptidase inhibitors. Cardiovasc Res 2001;51:416-26.

  33. Boomsma F, et al. Plams A and B type natriuretic peptides: Physiology, methodology and clinical use. Cardiovasc Res 2001;51:442-9.

  34. Nicholl MG. The natriuretic peptide in heart failure. J Intern Med 1994;235:515-26.

  35. Davison NC, et al. Comparison of atrial natriuretic peptide, B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction. Am J Cardiol 1996;77:828-3.

  36. Yoshimura M. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation 1991;84:1581-8.

  37. Holmes SJ, et al. renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocrinol Metab 1993;76:91-96.

  38. Lubien E, et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction. Circulation 2002;105:595-601.

  39. Colucci WS, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med 2002;343:246-53.

  40. Mills RM, et al. National Study Group Sustained hemodynamic effects of an infusion of nesiritide in heart failure. J Am Coll Cardiol 1999;34:155-62.

  41. Publication Committee for the VMAC Investigators: intravenous nesiritide vs nitroglicerin for treatment of decompensated heart failure a randomized controlled trial. JAMA 2002;287:1531-40.




2020     |     www.medigraphic.com